Health
ESMO Guidelines Discourage Delayed, Discontinued Treatment During the COVID-19 Pandemic – OncLive
Any type of anti-cancer therapy that could impact overall survival should not be discontinued or delayed.
Any type of anti-cancer therapy that could impact overall survival (OS) should not be discontinued or delayed, according to a European Society for Medical Oncology (ESMO) interdisciplinary expert consensus paper on how to manage patients with cancer during the coronavirus disease 2019 (COVID-19) pandemic.1
The guidelines, which were recently published in the Annals of Oncology,2 also discourage classifying all patients with cancer as especially vulnerable to COVID-19, regardless of age, gender,…
-
General21 hours agoEnglish springer spaniels Kelly and Milo helping fight dieback in Western Australia
-
General10 hours agoHow the internet reacted to Brisbane Broncos winning the NRL grand final
-
General20 hours agoHomicide Squad investigating ‘suspicious’ death of 84yo woman in Sydney suburb of Melonba
-
Noosa News18 hours agoMega-team of heavy horses sets world record at Good Old Days Festival